Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis

Jan Bucerius, Fabien Hyafil, Hein J Verberne, Riemer H J A Slart, Oliver Lindner, Roberto Sciagra, Denis Agostini, Christopher Übleis, Alessia Gimelli, Marcus Hacker, Cardiovascular Committee of the European Association of Nuclear Medicine (EANM), Jan Bucerius, Fabien Hyafil, Hein J Verberne, Riemer H J A Slart, Oliver Lindner, Roberto Sciagra, Denis Agostini, Christopher Übleis, Alessia Gimelli, Marcus Hacker, Cardiovascular Committee of the European Association of Nuclear Medicine (EANM)

Abstract

Cardiovascular diseases are the leading cause of death not only in Europe but also in the rest of the World. Preventive measures, however, often fail and cardiovascular disease may manifest as an acute coronary syndrome, stroke or even sudden death after years of silent progression. Thus, there is a considerable need for innovative diagnostic and therapeutic approaches to improve the quality of care and limit the burden of cardiovascular diseases. During the past 10 years, several retrospective and prospective clinical studies have been published using (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) to quantify inflammation in atherosclerotic plaques. However, the current variety of imaging protocols used for vascular (arterial) imaging with FDG PET considerably limits the ability to compare results between studies and to build large multicentre imaging registries. Based on the existing literature and the experience of the Members of the European Association of Nuclear Medicine (EANM) Cardiovascular Committee, the objective of this position paper was to propose optimized and standardized protocols for imaging and interpretation of PET scans in atherosclerosis. These recommendations do not, however, replace the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual study protocols used and the individual patient, in consultation with the patient and, where appropriate and necessary, the patient's guardian or carer. These recommendations suffer from the absence of conclusive evidence on many of the recommendations. Therefore, they are not intended and should not be used as "strict guidelines" but should, as already mentioned, provide a basis for standardized clinical atherosclerosis PET imaging protocols, which are subject to further and continuing evaluation and improvement. However, this EANM position paper might indeed be a first step towards "official" guidelines on atherosclerosis imaging with PET.

Keywords: Atherosclerosis; Position paper; Positron emission tomography.

Figures

Fig. 1
Fig. 1
Current most frequently used approaches to quantifying arterial FDG uptake in clinical studies. All values given are maximal target to background ratios (TBRmax). A TBR threshold of >1.6 was considered significant for the active segment analysis. The mean TBRmax of the whole vessel would be 1.99, and the mean TBRmax of the most diseased segment would be 2.63 (based on a graph by Tawakol et al. [64]). Image courtesy © Annette Bucerius

References

    1. WHO. Cardiovascular diseases (CVDs). Fact sheet no. 317. Geneva: World Health Organization; 2015. .
    1. Anderson GF, Chu E. Expanding priorities – confronting chronic disease in countries with low income. N Engl J Med. 2007;356:209–211. doi: 10.1056/NEJMp068182.
    1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, American Heart Association Statistics Committee and Stroke Statistics Subcommittee et al. Heart disease and stroke statistics – 2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–e322. doi: 10.1161/CIR.0000000000000152.
    1. Skålén K, Gustafsson M, Rydberg EK, Hultén LM, Wiklund O, Innerarity TL, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 2002;417:750–754. doi: 10.1038/nature00804.
    1. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 2001;104:503–516. doi: 10.1016/S0092-8674(01)00238-0.
    1. Miller YI, Chang MK, Binder CJ, Shaw PX, Witztum JL. Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol. 2003;14:437–445. doi: 10.1097/00041433-200310000-00004.
    1. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 2005;25:2054–2061. doi: 10.1161/01.ATV.0000178991.71605.18.
    1. Rudd JH, Hyafil F, Fayad ZA. Inflammation imaging in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1009–1016. doi: 10.1161/ATVBAHA.108.165563.
    1. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48:1818–1824. doi: 10.1016/j.jacc.2006.05.076.
    1. Figueroa AL, Subramanian SS, Cury RC, Truong QA, Gardecki JA, Tearney GJ, et al. Distribution of inflammation within carotid atherosclerotic plaques with high-risk morphological features: a comparison between positron emission tomography activity, plaque morphology, and histopathology. Circ Cardiovasc Imaging. 2012;5:69–77. doi: 10.1161/CIRCIMAGING.110.959478.
    1. Davies JR, Rudd JH, Fryer TD, Graves MJ, Clark JC, Kirkpatrick PJ, et al. Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke. 2005;36:2642–2647. doi: 10.1161/01.STR.0000190896.67743.b1.
    1. Fifer KM, Qadir S, Subramanian S, Vijayakumar J, Figueroa AL, Truong QA, et al. Positron emission tomography measurement of periodontal 18F-fluorodeoxyglucose uptake is associated with histologically determined carotid plaque inflammation. J Am Coll Cardiol. 2011;57:971–976. doi: 10.1016/j.jacc.2010.09.056.
    1. Bucerius J, Mani V, Moncrieff C, Machac J, Fuster V, Farkouh ME, et al. Optimizing 18F-FDG PET/CT imaging of vessel wall inflammation: the impact of 18F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels. Eur J Nucl Med Mol Imaging. 2014;41:369–383. doi: 10.1007/s00259-013-2569-6.
    1. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105:2708–2711. doi: 10.1161/01.CIR.0000020548.60110.76.
    1. Menezes LJ, Kotze CW, Hutton BF, Endozo R, Dickson JC, Cullum I, et al. Vascular inflammation imaging with 18F-FDG PET/CT: when to image? J Nucl Med. 2009;50:854–857. doi: 10.2967/jnumed.108.061432.
    1. Rudd JH, Machac J, Fayad ZA. Simvastatin and plaque inflammation. J Am Coll Cardiol. 2007;49:1991. Author reply 1991–2.
    1. Rudd JH, Fayad ZA, Machac J, Weissberg PL, Davies JR, Warburton EA, et al. Response to 'Laurberg JM, Olsen AK, Hansen SB, Bottcher M, Morrison M, Ricketts SA, Falk E. Imaging of vulnerable atherosclerotic plaques with FDG-microPET: no FDG accumulation' [Atherosclerosis 2006]. Atherosclerosis. 2007;192:453–4. Author reply 451–2.
    1. Rudd JH, Elkhawad M, Fayad ZA. Vascular imaging with 18F-FDG PET/CT: optimal 18F-FDG circulation time? J Nucl Med. 2009;50:1560. doi: 10.2967/jnumed.109.066456.
    1. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006;48:1825–1831. doi: 10.1016/j.jacc.2006.03.069.
    1. Blomberg BA, Thomassen A, Takx RA, Hildebrandt MG, Simonsen JA, Buch-Olsen KM, et al. Delayed 18F-fluorodeoxyglucose PET/CT imaging improves quantitation of atherosclerotic plaque inflammation: results from the CAMONA study. J Nucl Cardiol. 2014;21:588–597. doi: 10.1007/s12350-014-9884-6.
    1. Tawakol A, Migrino RQ, Hoffmann U, Abbara S, Houser S, Gewirtz H, et al. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol. 2005;12:294–301. doi: 10.1016/j.nuclcard.2005.03.002.
    1. Rabkin Z, Israel O, Keidar Z. Do hyperglycemia and diabetes affect the incidence of false-negative 18F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A comparative analysis. J Nucl Med. 2010;51:1015–1020. doi: 10.2967/jnumed.109.074294.
    1. Zhuang HM, Cortés-Blanco A, Pourdehnad M, Adam LE, Yamamoto AJ, Martínez-Lázaro R, et al. Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders? Nucl Med Commun. 2001;22:1123–1128. doi: 10.1097/00006231-200110000-00011.
    1. Lee WW, Chung JH, Jang SJ, Eo JS, Park SY, Sung SW, et al. Consideration of serum glucose levels during malignant mediastinal lymph node detection in non-small-cell lung cancer by FDG-PET. J Surg Oncol. 2006;94:607–613. doi: 10.1002/jso.20624.
    1. Shepherd PR, Kahn BB. Glucose transporters and insulin action – implications for insulin resistance and diabetes mellitus. N Engl J Med. 1999;341:248–257. doi: 10.1056/NEJM199907223410406.
    1. Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ, et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med. 2013;54:647–658. doi: 10.2967/jnumed.112.112524.
    1. Zhao S, Kuge Y, Tsukamoto E, Mochizuki T, Kato T, Hikosaka K, et al. Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesions. Eur J Nucl Med. 2001;28:730–735. doi: 10.1007/s002590100517.
    1. Zhao S, Kuge Y, Tsukamoto E, Mochizuki T, Kato T, Hikosaka K, et al. Fluorodeoxyglucose uptake and glucose transporter expression in experimental inflammatory lesions and malignant tumours: effects of insulin and glucose loading. Nucl Med Commun. 2002;23:545–550. doi: 10.1097/00006231-200206000-00006.
    1. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–354. doi: 10.1007/s00259-014-2961-x.
    1. Bucerius J, Mani V, Moncrieff C, Rudd JH, Machac J, Fuster V, et al. Impact of non insulin-dependent type 2 diabetes on carotid wall (18)F-fluorodeoxyglucose positron emission tomography uptake. J Am Coll Cardiol. 2012;59:2080–2088. doi: 10.1016/j.jacc.2011.11.069.
    1. Erlandsson K, Buvat I, Pretorius PH, Thomas BA, Hutton BF. A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology. Phys Med Biol. 2012;57:R119–R159. doi: 10.1088/0031-9155/57/21/R119.
    1. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932–945. doi: 10.2967/jnumed.106.035774.
    1. Burg S, Dupas A, Stute S, Dieudonné A, Huet P, Le Guludec D, et al. Partial volume effect estimation and correction in the aortic vascular wall in PET imaging. Phys Med Biol. 2013;58:7527–7542. doi: 10.1088/0031-9155/58/21/7527.
    1. Huet P, Burg S, Le Guludec D, Hyafil F, Buvat I. Variability and uncertainty of 18F-FDG PET imaging protocols for assessing inflammation in atherosclerosis: suggestions for improvement. J Nucl Med. 2015;56:552–559. doi: 10.2967/jnumed.114.142596.
    1. Petibon Y, El Fakhri G, Nezafat R, Johnson N, Brady T, Ouyang J. Towards coronary plaque imaging using simultaneous PET-MR: a simulation study. Phys Med Biol. 2014;59:1203–1222. doi: 10.1088/0031-9155/59/5/1203.
    1. Izquierdo-Garcia D, Davies JR, Graves MJ, Rudd JH, Gillard JH, Weissberg PL, et al. Comparison of methods for magnetic resonance-guided [18-F]fluorodeoxyglucose positron emission tomography in human carotid arteries: reproducibility, partial volume correction, and correlation between methods. Stroke. 2009;40:86–93. doi: 10.1161/STROKEAHA.108.521393.
    1. Ogawa M, Ishino S, Mukai T, Asano D, Teramoto N, Watabe H, et al. (18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med. 2004;45:1245–1250.
    1. Gholami S, Salavati A, Houshmand S, Werner TJ, Alavi A. Assessment of atherosclerosis in large vessel walls: A comprehensive review of FDG-PET/CT image acquisition protocols and methods for uptake quantification. J Nucl Cardiol. 2015;22:468–479. doi: 10.1007/s12350-015-0069-8.
    1. Zhao QM, Feng TT, Zhao X, Xu ZM, Liu Y, Li DP, et al. Imaging of atherosclerotic aorta of rabbit model by detection of plaque inflammation with fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography. Chin Med J (Engl) 2011;124:911–917.
    1. Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50:892–896. doi: 10.1016/j.jacc.2007.05.024.
    1. Figueroa AL, Abdelbaky A, Truong QA, Corsini E, MacNabb MH, Lavender ZR, et al. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events. JACC Cardiovasc Imaging. 2013;6:1250–1259. doi: 10.1016/j.jcmg.2013.08.006.
    1. Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med. 2008;49:871–878. doi: 10.2967/jnumed.107.050294.
    1. Bai B, Bading J, Conti PS. Tumor quantification in clinical positron emission tomography. Theranostics. 2013;3:787–801. doi: 10.7150/thno.5629.
    1. Bucerius J, Mani V, Wong S, Moncrieff C, Izquierdo-Garcia D, Machac J, et al. Arterial and fat tissue inflammation are highly correlated: a prospective 18F-FDG PET/CT study. Eur J Nucl Med Mol Imaging. 2014;41:934–945. doi: 10.1007/s00259-013-2653-y.
    1. Bucerius J, Vijgen GH, Brans B, Bouvy ND, Bauwens M, Rudd JH, et al. Impact of bariatric surgery on carotid artery inflammation and the metabolic activity in different adipose tissues. Medicine (Baltimore) 2015;94:e725. doi: 10.1097/MD.0000000000000725.
    1. Kim EJ, Kim S, Kang DO, Seo HS. Metabolic activity of the spleen and bone marrow in patients with acute myocardial infarction evaluated by 18F-fluorodeoxyglucose positron emission tomographic imaging. Circ Cardiovasc Imaging. 2014;7:454–460. doi: 10.1161/CIRCIMAGING.113.001093.
    1. Elkhawad M, Rudd JH, Sarov-Blat L, Cai G, Wells R, Davies LC, et al. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. JACC Cardiovasc Imaging. 2012;5:911–922. doi: 10.1016/j.jcmg.2012.02.016.
    1. Subramanian S, Emami H, Vucic E, Singh P, Vijayakumar J, Fifer KM, et al. High-dose atorvastatin reduces periodontal inflammation: a novel pleiotropic effect of statins. J Am Coll Cardiol. 2013;62:2382–2391. doi: 10.1016/j.jacc.2013.08.1627.
    1. Emami H, Vijayakumar J, Subramanian S, Vucic E, Singh P, MacNabb MH, et al. Arterial 18F-FDG uptake in rheumatoid arthritis correlates with synovial activity. JACC Cardiovasc Imaging. 2014;7:959–960. doi: 10.1016/j.jcmg.2014.03.018.
    1. Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol. 2013;62:909–917. doi: 10.1016/j.jacc.2013.04.066.
    1. Chen W, Dilsizian V. PET assessment of vascular inflammation and atherosclerotic plaques: SUV or TBR? J Nucl Med. 2015;56:503–504. doi: 10.2967/jnumed.115.154385.
    1. Emami H, Vucic E, Subramanian S, Abdelbaky A, Fayad ZA, Du S, et al. The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial. Atherosclerosis. 2015;240:490–496. doi: 10.1016/j.atherosclerosis.2015.03.039.
    1. Graebe M, Pedersen SF, Højgaard L, Kjaer A, Sillesen H. 18FDG PET and ultrasound echolucency in carotid artery plaques. JACC Cardiovasc Imaging. 2010;3:289–295. doi: 10.1016/j.jcmg.2010.01.001.
    1. Pedersen SF, Graebe M, Fisker Hag AM, Højgaard L, Sillesen H, Kjaer A. Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nucl Med Commun. 2010;31:423–429.
    1. Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009;50:1611–1620. doi: 10.2967/jnumed.109.065151.
    1. Marnane M, Merwick A, Sheehan OC, Hannon N, Foran P, Grant T, et al. Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Ann Neurol. 2012;71:709–718. doi: 10.1002/ana.23553.
    1. Abdelbaky A, Corsini E, Figueroa AL, Fontanez S, Subramanian S, Ferencik M, et al. Focal arterial inflammation precedes subsequent calcification in the same location: a longitudinal FDG-PET/CT study. Circ Cardiovasc Imaging. 2013;6:747–754. doi: 10.1161/CIRCIMAGING.113.000382.
    1. Tarkin JM, Rudd JH. Techniques for noninvasive molecular imaging of atherosclerotic plaque. Nat Rev Cardiol. 2014;12:79. doi: 10.1038/nrcardio.2014.80-c2.
    1. Ishii H, Nishio M, Takahashi H, Aoyama T, Tanaka M, Toriyama T, et al. Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention. Clin Ther. 2010;32:2337–2347. doi: 10.1016/j.clinthera.2010.12.001.
    1. Wu YW, Kao HL, Huang CL, Chen MF, Lin LY, Wang YC, et al. The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers. Eur J Nucl Med Mol Imaging. 2011;39:399–407. doi: 10.1007/s00259-011-1994-7.
    1. Fayad ZA, Mani V, Woodward M, Kallend D, Bansilal S, Pozza J, et al. Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Am Heart J. 2011;162:214–221. doi: 10.1016/j.ahj.2011.05.006.
    1. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011;378:1547–1559. doi: 10.1016/S0140-6736(11)61383-4.
    1. Gaztanaga J, Farkouh M, Rudd JH, Brotz TM, Rosenbaum D, Mani V, et al. A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome. Atherosclerosis. 2015;240:53–60. doi: 10.1016/j.atherosclerosis.2015.02.027.
    1. Tawakol A, Singh P, Rudd JH, Soffer J, Cai G, Vucic E, et al. Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with (18)F-fluorodeoxyglucose-positron emission tomography imaging. J Am Coll Cardiol. 2014;63:86–88. doi: 10.1016/j.jacc.2013.07.050.
    1. Shaddinger BC, Xu Y, Roger JH, Macphee CH, Handel M, Baidoo CA, et al. Platelet aggregation unchanged by lipoprotein-associated phospholipase A2 inhibition: results from an in vitro study and two randomized phase I trials. PLoS One. 2014;27:e8309.
    1. Judenhofer MS, Wehrl HF, Newport DF, Catana C, Siegel SB, Becker M, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med. 2008;14:459–465. doi: 10.1038/nm1700.
    1. Rischpler C, Nekolla SG, Dregely I, Schwaiger M. Hybrid PET/MR imaging of the heart: potential, initial experiences, and future prospects. J Nucl Med. 2013;54:402–415. doi: 10.2967/jnumed.112.105353.
    1. Bucerius J, Schmaljohann J, Böhm I, Guhlke S, Palmedo H, Schild HH, et al. Feasibility of 18-F-Fluoromethylcholine PET/CT for imaging of vessel wall alterations in humans – first results. Eur J Nucl Med Mol Imaging. 2008;35:815–820. doi: 10.1007/s00259-007-0685-x.
    1. Kato K, Schober O, Ikeda M, Schäfers M, Ishigaki T, Kies P, et al. Evaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:1622–1628. doi: 10.1007/s00259-009-1152-7.
    1. Förster S, Rominger A, Saam T, Wolpers S, Nikolaou K, Cumming P, et al. 18F-fluoroethylcholine uptake in arterial vessel walls and cardiovascular risk factors. Correlation in a PET-CT study. Nuklearmedizin. 2010;49:148–153. doi: 10.3413/nukmed-0299.
    1. Rominger A, Saam T, Vogl E, Übleis C, la Fougère C, Förster S, et al. In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors. J Nucl Med. 2010;51:193–197. doi: 10.2967/jnumed.109.070672.
    1. Folke Pedersen S, Vikjær Sandholt B, Høgild Keller S, Espe Hansen A, Ettrup Clemmensen A, Sillesen H, et al. 64Cu-DOTATATE PET/MRI for detection of activated macrophages in carotid atherosclerotic plaques: studies in patients undergoing endarterectomy. Arterioscler Thromb Vasc Biol. 2015;35:1696–1703. doi: 10.1161/ATVBAHA.114.305067.
    1. Derlin T, Richter U, Bannas P, Begemann P, Buchert R, Mester J, et al. Feasibility of 18F-sodium fluoride PET/CT for imaging of atherosclerotic plaque. J Nucl Med. 2010;51:862–865. doi: 10.2967/jnumed.110.076471.
    1. Irkle A, Vesey AT, Lewis DY, Skepper JN, Bird JL, Dweck MR, et al. Identifying active vascular microcalcification by (18)F-sodium fluoride positron emission tomography. Nat Commun. 2015;6:7495. doi: 10.1038/ncomms8495.
    1. Derlin T, Wisotzki C, Richter U, Apostolova I, Bannas P, Weber C, et al. In vivo imaging of mineral deposition in carotid plaque using 18F-sodium fluoride PET/CT: correlation with atherogenic risk factors. J Nucl Med. 2011;52:362–368. doi: 10.2967/jnumed.110.081208.
    1. Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet. 2014;383:705–713. doi: 10.1016/S0140-6736(13)61754-7.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa